Contact Us

Increased Risk Of Fatal Side Effects From 3 'Targeted' Cancer Drugs
Treatment with three relatively new targeted cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that the risk remains low, but should be taken into account by physicians and patients. The incidence of fatal complications was 1.5 percent in patients who received any of the three drugs, which block the vascular endothelial growth factor (VEGF) tyrosine kinase receptors in cancer cells, according to the study published February 6 in the Journal of Clinical Oncology... (Source: Health News from Medical News Today)div id=medwormpbiMedWorm Message:/i/b Register forba href=http://www.medmatcha.com target =_selfMedMatcha, MedWorm's medical advertising network/a/b, and receive $5 free advertising./p/div

As A Control Measure During Pandemic Outbreaks, School Closures Should Be Considered
Closing elementary and secondary schools can help slow the spread of infectious disease and should be considered as a control measure during pandemic outbreaks, according to a McMaster University led study. Using high-quality data about the incidence of influenza infections in Alberta during the 2009 H1N1 flu pandemic, the researchers show that when schools closed for the summer, the transmission of infection from person to person was sharply reduced... (Source: Health News from Medical News Today)

simethicone, Phazyme, Flatulex, Mylicon, Gas-X, Gas X Extra Strength, Mylanta Gas, Gas-X Ultra
Title: simethicone, Phazyme, Flatulex, Mylicon, Gas-X, Gas X Extra Strength, Mylanta Gas, Gas-X Ultra brCategory: MedicationsbrCreated: 6/8/1999 10:31:00 PMbrLast Editorial Review: 2/2/2012

Enzymatic Characterization and Elucidation of the Catalytic Mechanism of a Recombinant Bovine Glycine N-Acyltransferase [Articles]

Glycine conjugation, a phase II detoxification process, is catalyzed by glycine N-acyltransferase (GLYAT; E.C. 2.3.1.13). GLYAT detoxifies various xenobiotics, such as benzoic acid, and endogenous organic acids, such as isovaleric acid, which makes GLYAT important in the management of organic acidemias in humans. We cloned the open reading frame encoding the bovine ortholog of GLYAT from bovine liver mRNA into the bacterial expression vector pColdIII. The recombinant enzyme was expressed, partially purified, and enzymatically characterized. Protein modeling was used to predict Glu²²⁶ of bovine GLYAT to be catalytically important. This was assessed by constructing an E226Q mutant and comparing its enzyme kinetics to that of the wild-type recombinant bovine GLYAT. The Michaelis constants for benzoyl-CoA and glycine were determined and were similar for wild-type recombinant GLYAT, E226Q recombinant GLYAT, and GLYAT present in bovine liver. At pH 8.0, the E226Q mutant GLYAT had decreased activity, which could be compensated for by increasing the reaction pH. This suggested a catalytic mechanism in which Glu²²⁶ functions to deprotonate glycine, facilitating nucleophilic attack on the acyl-CoA. The recombinant bovine GLYAT enzyme, combined with this new understanding of its active site and reaction mechanism, could be a powerful tool to investigate the functional significance of GLYAT sequence variations. Eventually, this should facilitate investigations into the impact of known and novel sequence variations in the human GLYAT gene.

FDA panel to discuss Arena obesity drug in 2nd quarter (Reuters)
Reuters - An FDA advisory committee will meet in the second quarter to discuss Arena Pharmaceutical Inc's experimental obesity drug following the company's recent resubmission of an application seeking its approval, Arena said on Wednesday.

Non-Invasive DNA Test That Identifies Down Syndrome In Pregnancy Can Also Detect Trisomy 18 And Trisomy 13
A newly available DNA-based prenatal blood test that can identify a pregnancy with Down syndrome can also identify two additional chromosome abnormalities: trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome).The test for all three defects can be offered as early as 10 weeks of pregnancy to women who have been identified as being at high risk for these abnormalities. These are the results of an international, multicenter study published on-line today in the journal Genetics in Medicine... (Source: Health News from Medical News Today)